@srikosuri Best guess on minimally viable dose
8/ Sources 1. 2. 3. 4. 5. 6. 7. 8. 9. 10.…
8/ Sources
1. 2. 3. 4. 5. 6. 7. 8. 9. 10.…
6/ How Do we Measure Success: I’ll perform the following tests, implement my microdosing protocol, then retest after 12 weeks to determine success of the intervention. Metabolic Health: + Continuous glucose monitoring: Mean glucose, variability, peaks. + Insulin, HbA1c,…
6/ How Do we Measure Success:
I’ll perform the following tests, implement my microdosing protocol, then retest after 12 weeks to determine success of the intervention.
Metabolic Health:
+ Continuous glucose monitoring: Mean glucose, variability, peaks.
+ Insulin, HbA1c,…
7/ Conclusion Microdosing GLP-1-RAs represents a promising approach to leverage their potential longevity benefits while minimizing risks. Ongoing monitoring and consultation with healthcare professionals are crucial to ensure safety and efficacy.
7/ Conclusion
Microdosing GLP-1-RAs represents a promising approach to leverage their potential longevity benefits while minimizing risks. Ongoing monitoring and consultation with healthcare professionals are crucial to ensure safety and efficacy.
5/ Monitoring Potential Side Effects Even with microdosing, it’s essential to monitor for: Gastrointestinal Issues: Nausea and vomiting are common but less likely at low doses. Unintended Weight Loss: Increased satiety could lead to unintentional caloric restriction, I intend…
5/ Monitoring Potential Side Effects
Even with microdosing, it’s essential to monitor for:
Gastrointestinal Issues: Nausea and vomiting are common but less likely at low doses.
Unintended Weight Loss: Increased satiety could lead to unintentional caloric restriction, I intend…
3/ Possible Chronic Disease Risk Reduction Cardiovascular Health: semaglutide a GLP-1-RA has shown promise of lifespan extension in obese individuals by reducing the risk of cardiovascular disease. (12) Preclinical evidence also indicates improved endothelial function via…
3/ Possible Chronic Disease Risk Reduction
Cardiovascular Health: semaglutide a GLP-1-RA has shown promise of lifespan extension in obese individuals by reducing the risk of cardiovascular disease. (12)
Preclinical evidence also indicates improved endothelial function via…
4/ My Microdosing Protocol To evaluate the potential benefits I will start a 12 week trial of the GLP-1/GIP RA Tirzepatide (Commercial name: Munjaro for diabetes, Zepbound for weight loss). I'll start with a weekly dose of 0.5 mg, that is 1/2 the typical microdose, and 1/5 of…
4/ My Microdosing Protocol
To evaluate the potential benefits I will start a 12 week trial of the GLP-1/GIP RA Tirzepatide (Commercial name: Munjaro for diabetes, Zepbound for weight loss).
I'll start with a weekly dose of 0.5 mg, that is 1/2 the typical microdose, and 1/5 of…
1/ Here’s what I’m doing and why: What is a GLP-1RA? A GLP-1-RA is a medication that mimics the hormone glucagon-like peptide-1, crucial for regulating blood sugar and appetite. They’re approved for managing type 2 diabetes and aiding in weight loss by reducing blood sugar…
1/ Here’s what I’m doing and why:
What is a GLP-1RA? A GLP-1-RA is a medication that mimics the hormone glucagon-like peptide-1, crucial for regulating blood sugar and appetite. They’re approved for managing type 2 diabetes and aiding in weight loss by reducing blood sugar…
2/ Metabolic and Longevity Benefits Metabolic Optimization: Less glucose spikes, lower insulin levels, and thus reduced advanced glycation end-products (AGEs) (4, 5). Anti-Inflammatory Effects: Systemic inflammation reduction by decreasing pro-inflammatory cytokines like TNF-α…
2/ Metabolic and Longevity Benefits
Metabolic Optimization: Less glucose spikes, lower insulin levels, and thus reduced advanced glycation end-products (AGEs) (4, 5).
Anti-Inflammatory Effects: Systemic inflammation reduction by decreasing pro-inflammatory cytokines like TNF-α…
I'm starting a new longevity protocol: microdosing Tirzepatide, a dual GLP-1/GIP receptor agonist. Here is the existing evidence, my protocol, measurement plan, and what I expect to achieve by this intervention. 🧵
I'm starting a new longevity protocol: microdosing Tirzepatide, a dual GLP-1/GIP receptor agonist.
Here is the existing evidence, my protocol, measurement plan, and what I expect to achieve by this intervention. 🧵
